Introducing BrightHeart brainchild of Marilyne Levy, the groundbreaking medical equipment manufacturing startup revolutionizing prenatal ultrasound screening with the power of AI. With impressive seed funding of $2.1 million from renowned investor Sofinnova Partners, BrightHeart is based in Paris, France. Our mission is to ensure that every fetal ultrasound screening exam is performed with unparalleled accuracy, providing the highest quality of care to both mother and baby. Prenatal ultrasound screening is a complex procedure; up to 50% of congenital defects go undetected. BrightHeart is at the forefront of change, pioneering AI-driven software that offers real-time guidance to fetal medicine healthcare professionals.

With our cutting-edge technology, we enable consistent high-quality prenatal ultrasounds and provide valuable insights for optimal pregnancy and delivery management. BrightHeart has raised financing from Sofinnova Partners MD Start, supporting the development of our unique artificial intelligence software. They focus on improving the detection of congenital heart defects in fetuses, preparing regulatory submissions, and expanding our reach. Join them in shaping the future of prenatal ultrasound screening with BrightHeart's innovative AI solutions.